Conference Coverage

Watchman device hits home run in PROTECT AF trial

Publish date: May 30, 2013

 

AT HEART RHYTHM 2013

A fifth and final year of follow-up is scheduled for the PROTECT AF study.

The trial is sponsored by Boston Scientific. Dr. Reddy reported serving as a consultant to or receiving research grant support from Boston Scientific, Coherex Medical, and St. Jude Medical.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

FDA Reports Dabigatran Bleeds Don't Exceed Warfarin Bleeds
MDedge Neurology
Fine-Tuning Therapeutic Hypothermia After Cardiac Arrest
MDedge Neurology
Survival After In-Hospital Cardiac Arrest Has Improved Substantially
MDedge Neurology
Good news for apixaban in recurrent VTE prevention
MDedge Neurology
FDA makes dabigatran contraindicated for mechanical valves
MDedge Neurology
FDA approves apixaban for nonvalvular atrial fibrillation population
MDedge Neurology
PFOs raise stroke risk from ICDs, pacemakers
MDedge Neurology
VIDEO: Marijuana may raise stroke risk
MDedge Neurology
PFOs raise stroke risk from devices
MDedge Neurology
Apixaban, dabigatran found effective, safe for extended post-VTE therapy
MDedge Neurology